Pharmaceutical quality by design: Product and process development, understanding, and control

被引:877
作者
Yu, Lawrence X. [1 ]
机构
[1] US FDA, Off Gener Drugs, Rockville, MD 20855 USA
关键词
pharmaceutical quality by design; pharmaceutical quality by testing; process control; process design; process parameter; process variability; product design; quality attribute; question-based review;
D O I
10.1007/s11095-007-9511-1
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose. The purpose of this paper is to discuss the pharmaceutical Quality by Design (QbD) and describe how it can be used to ensure pharmaceutical quality. Materials and Methods. The QbD was described and some of its elements identified. Process parameters and quality attributes were identified for each unit operation during manufacture of solid oral dosage forms. The use of QbD was contrasted with the evaluation of product quality by testing alone. Results. The QbD is a systemic approach to pharmaceutical development. It means designing and developing formulations and manufacturing processes to ensure predefined product quality. Some of the QbD elements include: Defining target product quality profile Designing product and manufacturing processes Identifying critical quality attributes, process parameters, and sources of variability Controlling manufacturing processes to produce consistent quality over time Conclusions. Using QbD, pharmaceutical quality is assured by understanding and controlling formulation and manufacturing variables. Product testing confirms the product quality. Implementation of QbD will enable transformation of the chemistry, manufacturing, and controls (CMC) review of abbreviated new drug applications (ANDAs) into a science-based pharmaceutical quality assessment.
引用
收藏
页码:781 / 791
页数:11
相关论文
共 51 条
[1]  
Amidon GE, 2005, FDA OGD REGULATORY S
[2]  
AMIDON GE, 1995, PHYSICAL CHARACTERIZ, P281
[3]  
AMIDON GE, 2004, BURGERS MED CHEM DRU, V2, pCH18
[4]   A THEORETICAL BASIS FOR A BIOPHARMACEUTIC DRUG CLASSIFICATION - THE CORRELATION OF IN-VITRO DRUG PRODUCT DISSOLUTION AND IN-VIVO BIOAVAILABILITY [J].
AMIDON, GL ;
LENNERNAS, H ;
SHAH, VP ;
CRISON, JR .
PHARMACEUTICAL RESEARCH, 1995, 12 (03) :413-420
[5]  
[Anonymous], 2007, J GEN MED, DOI 10.1057/palgrave.jgm.4950073
[6]  
*ANT I PHAR TECHN, 2006, STRAT ROADM RES ED
[7]  
CHEN C, 2006, IMPLEMENTING QUALITY
[8]  
DELASKO JM, 2005, BEGINNING DRUG DEV E
[9]  
DUBIN H, 2005, DRUG DELIV TECHNOL, V5
[10]  
Food and Drug Administration, 2003, FIN REP PHARM CGMPS